GLP-1 Lab Monitoring: What Blood Tests You Actually Need (And When)

This is the part almost every page-1 competitor gets wrong. We checked the current labels on DailyMed — the NIH-hosted database that publishes the most recent labeling currently in use — for every major GLP-1 product, including the newer additions: Wegovy tablets, Ozempic tablets, Wegovy HD 7.2 mg, and Foundayo (orforglipron, FDA-approved April 1, 2026).

A history check, not a lab. Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, and Foundayo all carry a boxed warning making personal or family history of medullary thyroid carcinoma or MEN2 a contraindication. Both are answered by asking a question. No routine GLP-1 monitoring lab replaces it.

A specific instruction on routine thyroid screening that contradicts what most pages say. The current Wegovy and Ozempic labels both state, in plain language, that routine monitoring of serum calcitonin or routine thyroid ultrasound is “of uncertain value” for early MTC detection and “may lead to unnecessary procedures.” If you’ve been told you need calcitonin testing because you’re on a GLP-1, the label itself disagrees.

A kidney monitoring instruction that’s situation-specific. The labels tell clinicians to monitor renal function in patients with adverse reactions that could cause dehydration — severe nausea, vomiting, diarrhea. That’s a trigger, not a quarterly schedule.

A pancreatitis warning that’s symptom-driven. The labels list acute pancreatitis as a warning and instruct discontinuation if it’s suspected. They don’t endorse routine lipase as screening.

Glucose monitoring for diabetes patients. Current Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo labels say to monitor blood glucose before and during treatment in patients with diabetes. The Ozempic, Zepbound, Saxenda, Victoza, and Foundayo labels also specifically warn that the risk of low blood sugar goes up when the GLP-1 is combined with insulin or a sulfonylurea.

A gallbladder warning. Wegovy, Zepbound, and several other labels include warnings about acute gallbladder disease. The action is evaluation if symptoms occur — not imaging every patient.

A pulmonary aspiration warning. Current labels for Wegovy, Ozempic and Rybelsus tablets, Zepbound, Saxenda, and Foundayo include warnings about pulmonary aspiration during general anesthesia or deep sedation, tied to delayed gastric emptying.

So when a telehealth provider doesn’t order any labs before prescribing, that isn’t automatically negligence. The label doesn’t require it. What matters is whether the screening matches your risk profile.

Here’s the recommended baseline broken down by what each test tells you.

A1C — your average blood sugar over roughly the past three months (lab name: hemoglobin A1c or HbA1c). It’s the cheapest way to spot undiagnosed prediabetes or type 2 diabetes, and gives you the baseline to compare against later. Many people on a GLP-1 see their A1C drop into normal range over 6–12 months. Earns its spot for almost everyone. Cost: $34–$49 cash-pay through services like Personalabs or Quest Health.

CMP (comprehensive metabolic panel) — a 14-marker test covering kidney function (creatinine, eGFR, BUN), liver enzymes (ALT, AST, alkaline phosphatase), bilirubin, electrolytes, and fasting glucose. It’s the single most useful test because it answers four questions at once. Earns its spot for almost everyone. Cost: $44–$59 cash-pay.

Lipid panel — total cholesterol, LDL, HDL, triglycerides. The reason to do it now is to have a baseline you can compare against in 6–12 months, because lipid numbers usually improve with weight loss on a GLP-1. Earns its spot for most adults. Cost: $44–$59 cash-pay. Often covered at $0 by insurance as preventive screening under ACA rules.

Bundled at a direct-to-consumer service, all three usually land in the $130–$160 range in 2026.

Tests we’d skip for most healthy adults

• CBC (complete blood count) — useful for ruling out anemia or infection, but not GLP-1-specific. Add if you have fatigue, anemia history, or your prescriber wants a fuller picture. Optional.
• TSH (thyroid stimulating hormone) — checks thyroid function but does not screen for MTC (the cancer the boxed warning is about). Worth adding if you have thyroid symptoms or history. Cost: $49–$78 cash-pay.
• Pregnancy test — important if pregnancy is possible and your status is uncertain.
• Lipase or amylase — not endorsed for routine baseline use. The Saxenda label notes the clinical meaning of a mildly elevated lipase without symptoms is unknown. Not routine.
• Calcitonin — the labels say routine calcitonin monitoring is “of uncertain value.” Skip unless your clinician has a specific reason.
• Thyroid ultrasound — same logic. Skip for general screening.
• Vitamin D, B12, ferritin, broad hormone panels — general wellness tests, not GLP-1 safety tests.

The minimum reasonable baseline if money is tight: A1C, CMP, and lipid panel. About $130–$160 cash-pay. If you have insurance, ask the ordering office whether the lipid panel and A1C can be billed as preventive screening — coverage depends on your plan and the diagnosis code used.

If you have type 2 diabetes: The American Diabetes Association’s 2026 Standards of Care recommend A1C every three months when you’re changing therapy or not at your target, and every six months when you’re stable and at goal.

If you’re on a GLP-1 for weight loss only and you’re a healthy adult: Annual labs are reasonable for most people. A repeat A1C and CMP at 12 months covers the bulk of what changes. A lipid panel at 6–12 months is worth doing because that’s where the improvement shows up.

If you just had a dose increase: A recheck isn’t required by the label, but it’s a sensible time to check kidney function if you’ve had GI side effects during titration.

If you’ve had severe vomiting, diarrhea, or you can’t keep fluids down: Don’t wait for routine labs. The Wegovy, Zepbound, Ozempic, Foundayo, and Victoza labels all flag dehydration-related acute kidney injury as a real risk. A same-week CMP is the right move, plus a call to your prescriber.

A common over-monitoring trap: ordering a full lipid + thyroid + lipase + CBC panel every three months for a healthy adult on a GLP-1 for weight loss. There’s no evidence base or label requirement for that.

Calcitonin. Sold as MTC screening. The Wegovy and Ozempic labels state directly that routine calcitonin monitoring is “of uncertain value” and may lead to “unnecessary procedures.” A mildly elevated calcitonin in a healthy adult is more likely to be a benign finding that triggers an ultrasound, then a biopsy, then a worried specialist visit, than it is to detect a cancer the labels say it doesn’t reliably detect.

Thyroid ultrasound. Same logic. Unless you have a palpable nodule or concerning symptoms (a lump in the neck, hoarseness, trouble swallowing), routine ultrasound isn’t part of the FDA-endorsed monitoring plan.

Lipase as routine screening. The Saxenda label is the clearest — it notes that the clinical meaning of an elevated lipase or amylase in an asymptomatic patient is unknown. Lipase is the right test if you develop persistent upper-belly pain radiating to the back. It’s not the right test as a routine quarterly check.

Broad hormone panels. Some lab services market a “GLP-1 hormone panel” that includes cortisol, free testosterone, estradiol, DHEA-S, and a half-dozen other markers. None of these is in any current FDA label for GLP-1s.

Advanced lipid panels (ApoB, Lp(a), inflammation markers). Reasonable for serious cardiovascular risk assessment in high-risk patients. Not routine GLP-1 monitoring.

Vitamin and mineral panels. Vitamin D, B12, ferritin, magnesium, iron. Worth checking if you have specific symptoms, but not because you’re on a GLP-1.

The editorial line: a good lab plan is the shortest one that answers the questions your actual risk profile raises. Long panels feel thorough. They aren’t safer.

Acute kidney injury is the kidney concern that gets explicit attention in current GLP-1 labels. It’s been reported in patients on semaglutide, tirzepatide, liraglutide, orforglipron, and other agents in the class. The pattern is consistent: severe vomiting or diarrhea, poor fluid intake, dehydration, then a rise in creatinine.

What to check. A standard CMP includes creatinine and an estimated eGFR. That’s enough for most situations. Some clinicians add BUN and a urinalysis if they suspect another kidney issue.

When to recheck without waiting for a routine schedule:

• Persistent vomiting (more than a day)
• Persistent diarrhea (more than a few days)
• Dizziness, lightheadedness, or fainting when standing
• Unable to keep fluids down
• Sharp drop in urine output
• A new dose increase followed by severe GI symptoms

Pre-existing CKD changes the floor. If you already have stage 3 or higher chronic kidney disease, baseline labs aren’t optional — your prescriber needs them.

Medication interactions to surface with your clinician. Diuretics, ACE inhibitors, ARBs, and NSAIDs can all stress the kidneys, and the combination with GLP-1-related dehydration is what gets people in trouble. Don’t stop any of them on your own — flag them to your prescriber.

A practical message to send your provider: “I’ve had vomiting and diarrhea for [days] on my GLP-1. Should we check creatinine, eGFR, BUN, and electrolytes to make sure my kidneys are okay?”

Pancreatitis in plain language: severe, persistent pain in the upper-middle part of your belly that often radiates to your back, gets worse after eating, and usually comes with nausea and vomiting. It’s not the mild fullness many people have during titration. It’s pain bad enough that you’d consider going to urgent care.

Why routine lipase isn’t useful as screening:

• Mild lipase elevations are common on GLP-1 therapy and don’t necessarily mean pancreatitis
• The Saxenda label explicitly states the clinical meaning of an isolated mild elevation without symptoms is unknown
• A normal lipase last month doesn’t prevent pancreatitis next month

When lipase makes sense:

• You have a personal history of pancreatitis
• You develop upper-belly pain and your clinician is evaluating
• You have other clinical findings — gallstones, alcohol history, very high triglycerides — that raise the prior probability

The action if pancreatitis is suspected: Stop the GLP-1 (the label instructs this), call your prescriber, and consider urgent care.

For context on how GLP-1 side effect rates compare between clinical trials and real-world use, see our real-world evidence vs. clinical trial results guide.

TSH (thyroid stimulating hormone). Tests how well your thyroid gland is working. A normal TSH means your thyroid is producing the right amount of hormone. It does not rule out medullary thyroid carcinoma, because MTC arises from a different cell type (parafollicular C cells) than the cells that drive TSH. If you have thyroid symptoms, a TSH is reasonable. If you don’t, it’s an optional general health test, not a GLP-1 safety test.

Calcitonin. A hormone produced by the same C cells that can become cancerous in MTC. The FDA labels for semaglutide and liraglutide products specifically say that routine monitoring of serum calcitonin is “of uncertain value for early MTC detection and may lead to unnecessary procedures, given the low test specificity for serum calcitonin and the high background incidence of thyroid disease.” Don’t order it without a specific reason.

Thyroid ultrasound. Same FDA-label language — routine ultrasound has uncertain value for early MTC detection. Ultrasound makes sense if you have a palpable nodule, concerning symptoms, or your clinician identifies something on exam. Not a routine screen for every GLP-1 patient.

What actually catches the MTC contraindication: The intake question. “Do you or any blood relative have a history of medullary thyroid cancer, or a syndrome called MEN2?” If yes, the medication is contraindicated. No routine lab changes that.

A common confusion: “My telehealth provider didn’t order any thyroid labs — is that a red flag?” Not by itself. The labels don’t require routine thyroid labs. They require the history question. If your provider asked the question, they did the screening the label requires.

Two things can drive gallbladder issues in people taking a GLP-1: the medication itself and rapid weight loss in general, which is independently associated with gallstone formation.

Symptoms that change the plan:

• Pain in the right upper part of your belly, particularly after meals high in fat
• Pain that comes and goes in waves over hours
• Fever
• Nausea and vomiting that’s different from your usual GLP-1 side effects
• Yellowing of the skin or whites of the eyes (jaundice)
• Dark urine, pale stools

What gets tested if your clinician suspects gallbladder disease:

• Liver enzymes (ALT, AST, alkaline phosphatase)
• Bilirubin (total and direct)
• CBC if infection or inflammation is suspected
• Abdominal ultrasound — the imaging test of choice for gallstones and cholecystitis

The Wegovy and Zepbound labels both specifically say to do “gallbladder studies” and follow-up if cholelithiasis or cholecystitis is suspected. Not screened.

Stop-before-conception timing. If you’re planning a pregnancy, the medication needs to come off well before you start trying. The Wegovy label gives the 2-month figure. Semaglutide has a labeled elimination half-life of about 1 week and can remain in circulation for about 5–7 weeks after the last dose. Tirzepatide’s labeled half-life is about 5–6 days. Use the drug-specific stop timeline your prescriber gives you.

The oral birth control caveat — not just tirzepatide anymore. The tirzepatide products (Zepbound, Mounjaro) say to use a non-oral or backup contraceptive method for 4 weeks after starting and for 4 weeks after each dose escalation. The Foundayo label specifies 30 days after starting and 30 days after each dose escalation. The warning is about oral hormonal contraception (the pill) — not patches, rings, injections, implants, or IUDs, which use different absorption routes. Semaglutide products do not carry this specific backup-contraception recommendation.

If you became pregnant unexpectedly while on a GLP-1: Stop the medication and call your prescriber. The labels say to discontinue when pregnancy is recognized. This is a conversation for your prescriber, not the internet.

The mechanism is straightforward: GLP-1 medications slow stomach emptying. During general anesthesia or deep sedation, stomach contents can move into the airway (pulmonary aspiration), which is a serious complication.

What this means in practice:

• Disclose your GLP-1 to anyone scheduling you for surgery, an endoscopy, a colonoscopy, dental procedures involving sedation, or any other procedure with general anesthesia or deep sedation.
• Follow the hold instructions you’re given. Guidance is evolving and your care team will use the protocol that applies in your setting.
• Don’t stop your GLP-1 on your own without telling your prescriber, and don’t restart it post-procedure without checking with them.

Being upfront with your care team is the whole game here. Anesthesia teams have been increasingly aware of this issue, but you should never assume they’ve noticed your GLP-1 in your chart.

A1C schedule for type 2 diabetes:

• Baseline before or at the start of a GLP-1
• Every 3 months while titrating, changing medications, or not at your individualized target
• Every 6 months once you’re stable and at goal

That cadence comes directly from the ADA’s published Standards of Care.

The hypoglycemia issue. GLP-1s, by themselves, don’t typically cause low blood sugar — they only stimulate insulin release when blood sugar is already elevated. But if you’re already on insulin or a sulfonylurea like glipizide or glyburide, adding a GLP-1 means you may need less of those other drugs. If you don’t reduce the dose, you risk going low.

Hypoglycemia symptoms to know:

• Shakiness or trembling
• Sweating
• Confusion
• Weakness
• Fast or irregular heartbeat
• Dizziness or lightheadedness
• Severe symptoms (loss of consciousness, seizure) are an emergency

Diabetic retinopathy. The Ozempic, Zepbound, and Foundayo labels mention that patients with a history of diabetic retinopathy should be monitored for progression, particularly when blood sugar improves quickly. This isn’t a blood lab — it’s an eye exam. If you have known retinopathy, an eye check at baseline and during the first year on a GLP-1 is a reasonable cadence.

Mildly elevated liver enzymes (ALT, AST). Common in patients with fatty liver or higher BMI. On a GLP-1, ALT typically improves over months as weight comes off. The usual move is to recheck in a few months and watch the trend.

Reduced kidney function (high creatinine, low eGFR). If it’s mild and you weren’t recently dehydrated, your prescriber will probably want a recheck and a kidney-friendly hydration plan. If it’s severe or new and follows a bad GI episode, evaluation is more urgent.

Mildly elevated lipase or amylase without symptoms. Per the Saxenda label, the clinical significance is unknown. Most clinicians recheck and observe rather than stop the medication unless symptoms develop.

Abnormal TSH. Treat the thyroid condition and continue the GLP-1 as appropriate. TSH does not affect MTC contraindication status.

A new positive pregnancy test. Stop the medication and call your prescriber. The labels say to discontinue when pregnancy is recognized.

An MTC or MEN2 history surfacing after starting. Stop the medication and call your prescriber immediately. This is a contraindication regardless of how long you’ve been on the drug.

Severely elevated lipase plus pancreatitis symptoms. Treat as urgent. Stop the medication, call your prescriber, consider urgent care.

The general principle: an abnormal result is information, not a verdict. Share it with the person who prescribed the medication.

If your provider says “you don’t need labs”:

• Ask: Is that because I’m low-risk specifically, or because labs aren’t part of your protocol regardless of risk?
• Ask: What symptoms should trigger labs?
• Ask: Would you want to see any recent labs I already have?
• Ask: Do I need glucose monitoring based on my other medications?
• Ask: What’s the plan if I develop severe vomiting or diarrhea on this medication?

If your provider orders a long panel:

• Ask: Which of these tests is the FDA label asking for, and which are general health screening?
• Ask: Are any of these tests likely to give a result that wouldn’t change my plan?
• Ask: If I want to keep costs down, which tests would you prioritize?

These questions don’t put a clinician on the defensive — they give them an opening to explain their reasoning. Good clinicians appreciate it.

If you’re looking for a telehealth prescriber who will take the time for this conversation, see our review of Ro’s medical process or our guide to real-world GLP-1 evidence vs. clinical trial results.